Kesimpta® (ofatumumab) data show long-term preservation of IgG/IgM levels and no increased risk of serious infections in people living with multiple sclerosis

  • New ALITHIOS data show mean immunoglobulin G (IgG) levels in people treated with Kesimpta remained unchanged over 3.5 years and mean immunoglobulin M (IgM) levels remained within the reference range1 
  • Lower serum immunoglobulin levels, known to occur with other anti-CD20 therapies in MS patients, have been linked to an increased risk of infection, while immunoglobulin data with Kesimpta showed no association with risk of serious infections1, 2, 3 
  • Data …
/by